SynerGene Therapeutics, Inc. is a biopharmaceutical company developing targeted diagnostics and therapeutics in the areas of cancer, vaccine delivery, and neurological disorders. SynerGeneâs proprietary nanocomplex actively targets receptors present on diseased cells, delivering therapeutic drugs specifically to targeted sites while avoiding healthy cells. The companyâs nanocomplex is able to deliver numerous molecular medicines, including plasmid DNA, siRNA/miRNA, AS ODN, small molecules, chemotherapy drugs, and imaging agents. SynerGene has two products in human clinical trials. As of 2014, SGT-53 is being tested in a Phase Ib trial at MCCRC in combination with chemotherapeutic agent docetaxel in patients with various solid tumors. A new Phase Ib/II trial testing SGT-53 in combination with gemcitabine in pancreatic cancer is expected to begin shortly. SGT-94 is testing the delivery of another tumor suppressor gene, RB94, in a Phase I trial in patients with genitourinary tumor
